Advocacy intelligence hub — real-time data for patient organizations
Puma Biotechnology, Inc. — PHASE2
University Health Network, Toronto — PHASE2
Hunan Province Tumor Hospital — PHASE2
Moonlight Bio, Inc — PHASE1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — PHASE1
Sun Yat-sen University — PHASE2
National Cancer Institute (NCI) — PHASE1, PHASE2
National Cancer Institute (NCI) — PHASE1, PHASE2
Centre Georges Francois Leclerc
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Imdelltra
Amgen Inc.
Patient Assistance Programs9
Tagrisso
AstraZeneca Pharmaceuticals LP
IMFINZI
AstraZeneca Pharmaceuticals LP
TECENTRIQ
Genentech, Inc.
Gilotrif
Boehringer Ingelheim Pharmaceuticals, Inc.
KRAZATI
Mirati Therapeutics, Inc
Braftovi
Array BioPharma Inc. (a wholly owned subsidiary of Pfizer Inc.)
Imjudo
AstraZeneca Pharmaceuticals LP
CYRAMZA
Eli Lilly and Company
Zepzelca
Jazz Pharmaceuticals Ireland Limited
Zepzelca
(lurbinectedin)Orphan drugJazz Pharmaceuticals Ireland Limited
Alkylating Drug [EPC]
12.1 Mechanism of Action Lurbinectedin is an alkylating drug that binds guanine residues in the minor groove of DNA, forming adducts and resulting in ...
Imdelltra
(tarlatamab-dlle)Orphan drugAmgen Inc.
12.1 Mechanism of Action Tarlatamab-dlle is a bispecific T-cell engager that binds to DLL3 expressed on the surface of cells, including tumor cells, a...
TECENTRIQ
(atezolizumab)Orphan drugGenentech, Inc.
Programmed Death Receptor-1 Blocking Antibody [EPC]
12.1 Mechanism of Action PD L1 may be expressed on tumor cells and/or tumor infiltrating immune cells and can contribute to the inhibition of the anti...
OPDIVO
(NIVOLUMAB)standardE.R. Squibb & Sons, L.L.C.
Programmed Death Receptor-1 Blocking Antibody [EPC]
12.1 Mechanism of Action Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytoki...
Tagrisso
(osimertinib)Orphan drugstandardAstraZeneca Pharmaceuticals LP
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant ...
Abraxane
(paclitaxel protein-bound particles)Orphan drugstandardAbraxis BioScience, LLC
Microtubule Inhibitor [EPC]
12.1 Mechanism of Action ABRAXANE is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubule...
KRAZATI
(ADAGRASIB)acceleratedMirati Therapeutics, Inc
12.1 Mechanism of Action Adagrasib is an irreversible inhibitor of KRAS G12C that covalently binds to the mutant cysteine in KRAS G12C and locks the m...
Imjudo
(tremelimumab-actl)Orphan drugstandardAstraZeneca Pharmaceuticals LP
CTLA-4-directed Blocking Antibody [EPC]
12.1 Mechanism of Action CTLA-4 is a negative regulator of T-cell activity. Tremelimumab-actl is a monoclonal antibody that binds to CTLA-4 and blocks...
Opportunities and challenges of immunotherapy for patients with resectable and potentially resectable stage III non-small cell lung cancer.
The integration of immune checkpoint inhibitors has transformed the therapeutic landscape for patients with resectable and potentially resectable stage III non-small cell lung cancer, providing unprec...
Mapping the immune microenvironment of non-small cell lung cancer.
Immunotherapy is widely used in non-small cell lung cancer (NSCLC) treatment due to its significant efficacy. However, heterogeneity in treatment efficacy persists as a major challenge. The tumor immu...
Cryoablation as a Treatment Option for Early-Stage Primary Non-Small Cell Lung Cancer and Lung Metastases: A Narrative Review of Recent Literature.
Cryoablation has emerged as a promising treatment option for early-stage non-small cell lung cancer (NSCLC) and lung metastases. This narrative review examines recent literature on cryoablation's effi...
Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer.
Small cell lung cancer (SCLC) typically displays a "cold" tumor microenvironment with a paucity of immune infiltrate. Neuroendocrine SCLC cells also profoundly repress MHC-I expression, rendering them...
Editorial: Treatment response and resistance to targeted therapies for NSCLC.
Editorial: Treatment response and resistance to targeted therapies for NSCLC.
Strain-level genetic heterogeneity and colonization dynamics drive microbiome therapeutic efficacy.
Fecal microbiota transplantation (FMT) has shown immunotherapeutic promise, yet its efficacy in non-small-cell lung cancer (NSCLC) remains unclear. We demonstrate that FMT improves anti-PD-1 efficacy ...
Anurag Singh
Roswell Park Cancer Institute
Te-Chun Hsia
886422062121
Olivier MOLINIER, MD
CH Le Mans, France
Hui Liu, Professor
Sun yat-sen universtiy cancer center
Weijia Fang, M.D
Zhejiang University
Sant P Chawla, MD, M.D
Sarcoma Oncology Research Center
📍 SANTA MONICA, CA